https://www.selleckchem.com/products/MK-1775.html
Mirogabalin, which is a selective ligand of the α δ subunit of voltage-gated Ca channels, was recently approved in Japan for peripheral neuropathic pain. The α δ ligands, including mirogabalin and pregabalin, are associated with significant risk of adverse events (AEs) such as somnolence or dizziness, leading to poor compliance and subsequent inefficacy. Safety and efficacy data for switching patients from pregabalin to mirogabalin are scarce. This prospective, single-arm, open-label study involving ten participating centers in Japan re
Like
Comment
Share
